title: A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.
abstract: Benznidazole (BZN) is the main trypanocidal drug used to treat Chagas disease, and the evidence supporting the benefits of BZN use during the chronic phase of the disease will favor its use in millions of individuals. However, more than 30% of patients treated with BZN may suffer adverse drug reactions (ADRs), and the development of tools to identify those patients at risk is highly desirable. In the present study, we aimed to identify predictive factors for ADRs in Chagas disease patients treated with BZN. Among 195 patients included in the study, 48.7% experienced ADRs and 31.3% had ADRs that caused BZN treatment discontinuation. Overall ADRs and ADRs that caused BZN treatment discontinuation were more common among women and in those who graduated from elementary school. Overall ADRs were also less frequent among black individuals. Based on logistic regression analysis, female sex (odds ratio [OR], 2.9; 95% confidence interval [CI], 1.5 to 5.4), graduation from elementary school (OR, 2.0; 95% CI, 1.1 to 3.8), and white (OR, 5.0; 95% CI, 1.0 to 24.1) and mulatto (OR, 5.6; 95% CI, 1.1 to 28.7) races were considered to predict overall ADRs, and female sex (OR, 2.3; 95% CI, 1.2 to 4.3) was considered to predict ADRs that caused BZN treatment discontinuation. Graduation from elementary school also presented a tendency to predict ADRs that caused BZN treatment discontinuation (OR, 1.8; 95% CI, 0.9 to 3.6). The logistic regression (LR) models to predict ADRs to BZN described in this study may become important tools to minimize ADRs and improve patients' compliance and thus assist physicians treating patients with Chagas disease with BZN.
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil gilbertomarcelo@gmail.com.
authors.forename: Gilberto Marcelo
authors.initials: GM
authors.lastname: Sperandio da Silva
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Mauro Felippe Felix
authors.initials: MF
authors.lastname: Mediano
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Pedro Emmanuel
authors.initials: PE
authors.lastname: Alvarenga Americano do Brasil
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Mayara
authors.initials: M
authors.lastname: da Costa Chambela
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Joyce Almeida
authors.initials: JA
authors.lastname: da Silva
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Andrea Silvestre
authors.initials: AS
authors.lastname: de Sousa
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Sergio Salles
authors.initials: SS
authors.lastname: Xavier
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Andrea
authors.initials: A
authors.lastname: Rodrigues da Costa
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Roberto
authors.initials: R
authors.lastname: Magalhães Saraiva
authors.affiliation: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Alejandro Marcel
authors.initials: AM
authors.lastname: Hasslocher-Moreno
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D015415:Biomarkers; D014355:Chagas Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000469:parasitology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D004522:Educational Status; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D009593:Nitroimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D044469:Racial Groups; D012737:Sex Factors; D014344:Trypanocidal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014349:Trypanosoma cruzi / Q000187:drug effects; D055815:Young Adult
chemical_list: D015415:Biomarkers; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; C009999:benzonidazole
references.citation: Acta Trop. 2010 Jul-Aug;115(1-2):22-7
references.pmid: 19646412
references.citation: Rev Inst Med Trop Sao Paulo. 2002 Jan-Feb;44(1):29-37
references.pmid: 11896410
references.citation: Int J Qual Health Care. 2000 Feb;12(1):69-76
references.pmid: 10733086
references.citation: Chem Biol Interact. 1990;73(1):1-27
references.pmid: 2406032
references.citation: Lancet. 2010 Apr 17;375(9723):1388-402
references.pmid: 20399979
references.citation: PLoS Negl Trop Dis. 2009 Jul 07;3(7):e488
references.pmid: 19582142
references.citation: Acta Trop. 2010 Jul-Aug;115(1-2):14-21
references.pmid: 19932071
references.citation: Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:17-30
references.pmid: 19753454
references.citation: Medicina (B Aires). 1999;59 Suppl 2:147-65
references.pmid: 10668258
references.citation: N Engl J Med. 2011 Jun 30;364(26):2527-34
references.pmid: 21714649
references.citation: Ann Dermatol. 2011 Nov;23(4):432-8
references.pmid: 22148009
references.citation: Lancet. 1996 Nov 23;348(9039):1407-13
references.pmid: 8937280
references.citation: J Biomed Inform. 2002 Oct-Dec;35(5-6):352-9
references.pmid: 12968784
references.citation: Br J Clin Pharmacol. 2011 May;71(5):684-700
references.pmid: 21480948
references.citation: Clin Pharmacol Ther. 1981 Aug;30(2):239-45
references.pmid: 7249508
references.citation: PLoS One. 2011;6(8):e23137
references.pmid: 21887234
references.citation: J Allergy Clin Immunol. 2004 May;113(5):832-6
references.pmid: 15131563
references.citation: Hum Exp Toxicol. 2010 Oct;29(10):813-22
references.pmid: 20150355
references.citation: PLoS Negl Trop Dis. 2010 Jun 29;4(6):e645
references.pmid: 20614014
references.citation: Rev Soc Bras Med Trop. 2005;38 Suppl 3:7-29
references.pmid: 16416933
references.citation: Antimicrob Agents Chemother. 2010 Nov;54(11):4896-9
references.pmid: 20823286
references.citation: Hum Exp Toxicol. 2006 Aug;25(8):471-9
references.pmid: 16937919
references.citation: Clin Pharmacol Ther. 2011 Jun;89(6):845-54
references.pmid: 21508941
references.citation: Infect Dis Clin North Am. 2012 Jun;26(2):275-91
references.pmid: 22632639
references.citation: Trop Med Int Health. 2010 Nov;15(11):1281-8
references.pmid: 20976871
references.citation: JAMA. 2007 Nov 14;298(18):2171-81
references.pmid: 18000201
references.citation: Pediatrics. 2011 Jan;127(1):e212-8
references.pmid: 21173000
references.citation: Rev Esp Quimioter. 2011 Sep;24(3):123-6
references.pmid: 21947093
references.citation: Curr Infect Dis Rep. 2012 Jun;14(3):263-74
references.pmid: 22477037
references.citation: PLoS Negl Trop Dis. 2013 Sep 19;7(9):e2407
references.pmid: 24069472
references.citation: Pharmacoepidemiol Drug Saf. 2010 Mar;19(3):247-55
references.pmid: 20066675
references.citation: Arch Intern Med. 2010 Jul 12;170(13):1142-8
references.pmid: 20625022
references.citation: Am Fam Physician. 2003 Nov 1;68(9):1781-90
references.pmid: 14620598
references.citation: J Antimicrob Chemother. 2009 Dec;64(6):1139-47
references.pmid: 19819909
references.citation: Expert Rev Anti Infect Ther. 2009 Mar;7(2):157-63
references.pmid: 19254164
references.citation: Cochrane Database Syst Rev. 2014 May 27;(5):CD003463
references.pmid: 24867876
references.citation: Ann Pharmacother. 2005 Jul-Aug;39(7-8):1161-8
references.pmid: 15897265
references.citation: Curr Opin Allergy Clin Immunol. 2001 Aug;1(4):305-10
references.pmid: 11964705
references.citation: J Allergy Clin Immunol. 2008 Oct;122(4):820-827.e9
references.pmid: 19014772
references.citation: Ann Intern Med. 2006 May 16;144(10):724-34
references.pmid: 16702588
references.citation: J Antimicrob Chemother. 2012 May;67(5):1261-6
references.pmid: 22331592
references.citation: BMC Pharmacol Toxicol. 2013 Jan 08;14:5
references.pmid: 23298396
references.citation: Rev Soc Bras Med Trop. 2010 Mar-Apr;43(2):182-7
references.pmid: 20464150